Themis Medicare Limited · NSE:THEMISMED
Themis Medicare — Q3 FY26 Earnings Presentation
19 slides from Themis Medicare's earnings presentation, Feb 13, 2026
Slide 1: Stock exchange filing cover letter: Investor Presentation
TML/BSE/NSE/2025-26/51 13th February, 2026 Corporate Relationship Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Dalal Street, Mumbai- 400001 Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Scrip Code – 530199 Symbol:
Slide 2: Result Update Presentation Q3 & 9M FY26
In every possibility lies an innate, latent power to change lives Themis Medicare Ltd. Result Update Presentation Q3 & 9M FY26
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Themis Medicare Limited (the “Company” or “Themis” or “TML”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in
Slide 4: Table of Contents
Table of Contents Consolidated Financial Highlights Company Overview Way Ahead 3
Slide 5: Management Comment
Management Comment Commenting on the result, Dr. Sachin Patel, Managing Director & CEO, said: “The third quarter witnessed a positive turn-around for the Company in terms of profitability, despite pressure on top line. Disruption in a significant line of Business continued through this quarter, howe
Slide 6: Consolidated Financial Highlights
Consolidated Financial Highlights
Slide 7: Consolidated Quarterly Financial Highlights
Consolidated Quarterly Financial Highlights Revenue (Rs. Cr.)* EBITDA (Rs. Cr.)** / Margin (%) 10.9% 93.8 97.6 90.1 9.1% 78.0 71.7 8.5 -5.8 9.8 -10.1 -3.1 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 -4.0% -8.1% Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 -10.3% PAT (Rs. Cr.) / Margin (%) EPS (Rs.) 11.2% 0.6
Slide 8: Consolidated Quarterly Financial Highlights – Q3 FY26
Consolidated Quarterly Financial Highlights – Q3 FY26 Particulars (Rs. Cr.) Q3 FY26 Q3 FY25 Y-o-Y (%) Q2 FY26 Net Revenue 90.13 93.81 (3.9%) 77.99 Cost of Material Consumed 14.50 12.76 16.11 • Continued growth in API Purchase of SIT 11.63 22.51 18.23 business, partially offset Changes in Inventory 3
Slide 9: Consolidated Financial Highlights – 9M FY26
Consolidated Financial Highlights – 9M FY26 Particulars (Rs. Cr.) 9M FY26 9M FY25 Y-o-Y (%) Net Revenue 265.71 333.81 (20.4%) Cost of Material Consumed 43.03 57.33 Purchase of SIT 51.54 57.37 Changes in Inventory 11.15 (3.30) Employee Expenses 72.46 70.92 Other Expenses 90.90 96.65 Total Expenditure
Slide 10: Consolidated Balance Sheet as on 30th Sep'25
Consolidated Balance Sheet as on 30th Sep’25 As on 30th As on 31st As on 30th As on 31st Equity & Liabilities Assets Sep’25 Mar’25 Sep’25 Mar’25 Shareholders Funds 380.01 402.60 Non Current Assets 283.49 284.17 Share Capital 9.20 9.20 Plant, Property & Equipment 168.69 172.03 Other Equity 370.80 393
Slide 11: Company Overview
Company Overview
Slide 12: Snapshot of Company
Snapshot of Company Strategic focus To become Leader in Hospital Business in India with 4 Strong Balance Sheet growing divisions contributing 38.25% to revenue in Total Debt to Equity at 0.21 FY24-25 in FY24-25 3 State of art manufacturing facilities in India – Rs. 927 Cr 1 Formulations and 2 APIs (
Slide 13: Strong Business Model
Strong Business Model 01 Businesswise Revenue – 9M FY26 Hospital Business API, Co. Mkt & Others 23% is major growth 03 Hospital driver Trade 49% 28% n 02 n Hospital Business API Business Critical Care Division API Legacy Business Intensive Care Division New Product pipeline Businesswise Reve
Slide 14: Vertically Integrated State of Art Manufacturing Capabilities
Vertically Integrated State of Art Manufacturing Capabilities Location Particulars Haridwar Hyderabad Vapi Artemis Biotech Themis Medicare Ltd. Themis Medicare Ltd. (Division of Themis Medicare Ltd.) Segment Formulations Synthetic APIs Synthetic APIs Tablets (Nos.) - 520 mn Ointment (No. of Tubes) -
Slide 15: Strong Research and Development Capabilities
Strong Research and Development Capabilities Continued Investment in R&D (Rs. Cr.) Business API Formulations 14.25 13.64 13.69 13.21 R&D 10 1 Analytical Lab 8.50 5 8 Development Product in a year with 5–8 20-24 documentation FY20-21 FY21-22 FY22-23 FY23-24 FY24-25 Products in work rolling 3–5 31 14
Slide 16: Way Ahead
Way Ahead
Slide 17: Hospital Business Opportunity
n Hospital Business Opportunity Why Hospital Business Segment? Growing market - Themis has strong foot in door through Critical Care Market Highly Fragmented unlike West where 3-4 players control 90% market share Opportunities to grow segments within HB High Entry Barriers Large Product Port
Slide 18: Our Aspirations
Our Aspirations Vision & Position Provide hospitals and health systems ‘The Best Experience Leader business model” to ensure customer satisfaction Leadership in Anesthesia and Critical Care Strategy Focus on Hospital business New Target Markets APIs to be developed - in- house consumption an
Slide 19: Thank You
Thank You It takes one word to change the world “POSSIBILITY” For further information, please contact: Mr. Pradeep Chandan Mr. Amit Sharma / Mr. Rahul Trivedi Tel: +91 9867726686 / 9833541841 Themis Medicare Ltd Email: pradeep.chandan@themismedicare.com Adfactors PR Pvt Ltd Website: www.themismedica